Cargando…

Fecal Microbiota Transplantation in Liver Cirrhosis

The human gastrointestinal tract houses a diverse array of probiotic and pathogenic bacteria and any alterations in this microbial composition can exert a significant influence on an individual’s well-being. It is well-established that imbalances in the gut microbiota play a pivotal role in the deve...

Descripción completa

Detalles Bibliográficos
Autores principales: Boicean, Adrian, Birlutiu, Victoria, Ichim, Cristian, Brusnic, Olga, Onișor, Danusia Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10668969/
https://www.ncbi.nlm.nih.gov/pubmed/38001930
http://dx.doi.org/10.3390/biomedicines11112930
_version_ 1785139587899719680
author Boicean, Adrian
Birlutiu, Victoria
Ichim, Cristian
Brusnic, Olga
Onișor, Danusia Maria
author_facet Boicean, Adrian
Birlutiu, Victoria
Ichim, Cristian
Brusnic, Olga
Onișor, Danusia Maria
author_sort Boicean, Adrian
collection PubMed
description The human gastrointestinal tract houses a diverse array of probiotic and pathogenic bacteria and any alterations in this microbial composition can exert a significant influence on an individual’s well-being. It is well-established that imbalances in the gut microbiota play a pivotal role in the development of liver diseases. In light of this, a new adjuvant therapy for liver diseases could be regulating the intestinal microbiota. Through fecal microbiota transplantation, patients whose microbiomes are compromised are treated with stool from healthy donors in an attempt to restore a normal microbiome and alleviate their symptoms. A review of cross-sectional studies and case reports suggests that fecal microbiota transplants may offer effective treatment for chronic liver diseases. Adding to the potential of this emerging therapy, recent research has indicated that fecal microbiota transplantation holds promise as a therapeutic approach specifically for liver cirrhosis. By introducing a diverse range of beneficial microorganisms into the gut, this innovative treatment aims to address the microbial imbalances often observed in cirrhotic patients. While further validation is still required, these preliminary findings highlight the potential impact of fecal microbiota transplantation as a novel and targeted method for managing liver cirrhosis. We aimed to summarize the current state of understanding regarding this procedure, as a new therapeutic method for liver cirrhosis, as well as to explain its clinical application and future potential.
format Online
Article
Text
id pubmed-10668969
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106689692023-10-30 Fecal Microbiota Transplantation in Liver Cirrhosis Boicean, Adrian Birlutiu, Victoria Ichim, Cristian Brusnic, Olga Onișor, Danusia Maria Biomedicines Review The human gastrointestinal tract houses a diverse array of probiotic and pathogenic bacteria and any alterations in this microbial composition can exert a significant influence on an individual’s well-being. It is well-established that imbalances in the gut microbiota play a pivotal role in the development of liver diseases. In light of this, a new adjuvant therapy for liver diseases could be regulating the intestinal microbiota. Through fecal microbiota transplantation, patients whose microbiomes are compromised are treated with stool from healthy donors in an attempt to restore a normal microbiome and alleviate their symptoms. A review of cross-sectional studies and case reports suggests that fecal microbiota transplants may offer effective treatment for chronic liver diseases. Adding to the potential of this emerging therapy, recent research has indicated that fecal microbiota transplantation holds promise as a therapeutic approach specifically for liver cirrhosis. By introducing a diverse range of beneficial microorganisms into the gut, this innovative treatment aims to address the microbial imbalances often observed in cirrhotic patients. While further validation is still required, these preliminary findings highlight the potential impact of fecal microbiota transplantation as a novel and targeted method for managing liver cirrhosis. We aimed to summarize the current state of understanding regarding this procedure, as a new therapeutic method for liver cirrhosis, as well as to explain its clinical application and future potential. MDPI 2023-10-30 /pmc/articles/PMC10668969/ /pubmed/38001930 http://dx.doi.org/10.3390/biomedicines11112930 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Boicean, Adrian
Birlutiu, Victoria
Ichim, Cristian
Brusnic, Olga
Onișor, Danusia Maria
Fecal Microbiota Transplantation in Liver Cirrhosis
title Fecal Microbiota Transplantation in Liver Cirrhosis
title_full Fecal Microbiota Transplantation in Liver Cirrhosis
title_fullStr Fecal Microbiota Transplantation in Liver Cirrhosis
title_full_unstemmed Fecal Microbiota Transplantation in Liver Cirrhosis
title_short Fecal Microbiota Transplantation in Liver Cirrhosis
title_sort fecal microbiota transplantation in liver cirrhosis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10668969/
https://www.ncbi.nlm.nih.gov/pubmed/38001930
http://dx.doi.org/10.3390/biomedicines11112930
work_keys_str_mv AT boiceanadrian fecalmicrobiotatransplantationinlivercirrhosis
AT birlutiuvictoria fecalmicrobiotatransplantationinlivercirrhosis
AT ichimcristian fecalmicrobiotatransplantationinlivercirrhosis
AT brusnicolga fecalmicrobiotatransplantationinlivercirrhosis
AT onisordanusiamaria fecalmicrobiotatransplantationinlivercirrhosis